JP2022539016A5 - - Google Patents

Info

Publication number
JP2022539016A5
JP2022539016A5 JP2021576404A JP2021576404A JP2022539016A5 JP 2022539016 A5 JP2022539016 A5 JP 2022539016A5 JP 2021576404 A JP2021576404 A JP 2021576404A JP 2021576404 A JP2021576404 A JP 2021576404A JP 2022539016 A5 JP2022539016 A5 JP 2022539016A5
Authority
JP
Japan
Prior art keywords
cancer
virus
oncolytic virus
oncolytic
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021576404A
Other languages
English (en)
Japanese (ja)
Other versions
JP7704419B2 (ja
JP2022539016A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2020/008472 external-priority patent/WO2020263059A1/ko
Publication of JP2022539016A publication Critical patent/JP2022539016A/ja
Publication of JP2022539016A5 publication Critical patent/JP2022539016A5/ja
Application granted granted Critical
Publication of JP7704419B2 publication Critical patent/JP7704419B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021576404A 2019-06-27 2020-06-29 安全性及び抗がん効果が改善された腫瘍溶解性ウイルス Active JP7704419B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2019-0077377 2019-06-27
KR20190077377 2019-06-27
PCT/KR2020/008472 WO2020263059A1 (ko) 2019-06-27 2020-06-29 안전성 및 항암효과가 개선된 항암바이러스

Publications (3)

Publication Number Publication Date
JP2022539016A JP2022539016A (ja) 2022-09-07
JP2022539016A5 true JP2022539016A5 (enExample) 2023-06-19
JP7704419B2 JP7704419B2 (ja) 2025-07-08

Family

ID=74060325

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021576404A Active JP7704419B2 (ja) 2019-06-27 2020-06-29 安全性及び抗がん効果が改善された腫瘍溶解性ウイルス

Country Status (8)

Country Link
US (1) US20220202885A1 (enExample)
EP (1) EP3992281A4 (enExample)
JP (1) JP7704419B2 (enExample)
KR (1) KR102625842B1 (enExample)
CN (1) CN114096661B (enExample)
AU (1) AU2020306544B2 (enExample)
CA (1) CA3139643A1 (enExample)
WO (1) WO2020263059A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120037270A (zh) * 2019-08-26 2025-05-27 拜耳诺克斯有限公司 包含痘苗病毒和羟基脲作为活性成分的用于治疗癌症的药物组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2699191B1 (fr) * 1992-12-16 1995-02-10 Univ Paris Curie Nouveaux vecteurs rétroviraux, lignées cellulaires les contenant, et leur utilisation dans le traitement des tumeurs.
BR9707483A (pt) 1996-02-09 1999-04-06 Rhone Poulenc Rorer Sa Sequência de ácidos nucléicos que codificam para uma timidina quinase variante de uma timidina quinase selvagem variante de uma timidina quinase do vírus do herpes simplex de tipo 1 veículo de expressão vetor e composição farmacêutica
GB0008966D0 (en) * 2000-04-13 2000-05-31 Imp College Innovations Ltd Vectors for gene therapy
WO2002042468A2 (en) * 2000-11-27 2002-05-30 Geron Corporation Glycosyltransferase vectors for treating cancer
US20040053836A1 (en) 2002-04-22 2004-03-18 Philipp Mayer-Kuckuk Method for modulating the production of a selected protein in vivo
GB0413702D0 (en) * 2004-06-18 2004-07-21 Molmed Spa Thymidine kinase
CN105407902A (zh) * 2013-03-05 2016-03-16 贝勒医学院 溶瘤病毒
EP2967078B1 (en) 2013-03-14 2018-10-17 GenVivo, Inc. Thymidine kinase diagnostic assay for gene therapy applications
KR20190059421A (ko) * 2017-11-23 2019-05-31 주식회사 바이오녹스 항암바이러스의 간동맥 투여를 이용한 간암 치료방법
WO2019108777A1 (en) * 2017-11-29 2019-06-06 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
AU2018395012B2 (en) * 2017-12-28 2022-03-10 Bionoxx Inc. Oncolytic virus improved in safety and anticancer effect
CN114630683A (zh) * 2019-08-29 2022-06-14 拜耳诺克斯有限公司 包含痘苗病毒和粒细胞生成抑制剂作为活性成分的用于治疗癌症的药物组合物

Similar Documents

Publication Publication Date Title
US12291726B2 (en) A549 host cells comprising a recombinant oncolytic adenovirus with modified E1A cancer-specific promoter
JP2020524993A5 (enExample)
ES2212815T3 (es) Virus citopaticos para la terapia y profilaxis de neoplasia.
WO2019080537A1 (zh) 包含溶瘤病毒和car-nk细胞的治疗剂及应用、药盒、治疗肿瘤和/或癌症的方法
Cao et al. Gene therapy for hepatocellular carcinoma based on tumour-selective suicide gene expression using the alpha-fetoprotein (AFP) enhancer and a housekeeping gene promoter
McLeod et al. Therapeutic opportunities from tumour biology in metastatic colon cancer
RU2011136280A (ru) HE-Ad5 АДЕНОВИРУСНЫЕ ВЕКТОРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
WO2021258492A1 (zh) 甲硫氨酸酶的基因疗法在治疗恶性肿瘤中的应用
US20100015700A1 (en) Use of the adenoviral e2 late promoter
CN114096661B (zh) 改进了安全性及抗肿瘤效果的溶瘤病毒
US10370647B2 (en) Host regulatory factor that enhances replication and/or propagation of vaccinia virus
Tang et al. A chimeric oncolytic adenovirus carried by macrophages for glioma immunotherapy
US7371570B2 (en) Cell-specific adenovirus vector comprising EBV-specific promoter
CN112513281B (zh) 抗肿瘤组合物
Vidal et al. Reovirus and other oncolytic viruses for the targeted treatment of cancer
US20110166207A1 (en) Use of aav integration efficiency element for mediating site-specific integration of a transcription unit
Kosmidis et al. Gene therapy for hepatocellular carcinoma: An update
KR20110140108A (ko) 아데닐레이트 싸이클라제 활성화 폴리펩타이드 1 (뇌하수체)의 유전자를 함유하는 자궁경부암세포의 증식 억제용 재조합벡터 및 자궁경부암 치료용 약학 조성물
JP2021507718A (ja) 遺伝子伝達用細胞シート
Iida et al. Enhancement of cyclophosphamide sensitivity in squamous cell carcinoma transfected with cytochrome P-450 2B1
Gao et al. Bone Marrow Mesenchymal Stem Cells (BMSCs) with a Disintegrin and Metalloprotease 17 (ADAM17) Overexpression Increase Cervical Cancer Cell Proliferation and Migration Through Epidermal Growth Factor Receptor (EGFR)/Phosphatidylinositol 3-Kinase (PI3K)/Protein Kinase b (AKT) Signaling
JP2005021110A (ja) Ｃｄ３０リガンドおよび／またはｃｄ３０の発現誘導剤、アポトーシス誘導剤ならびにそれらを含有する医薬組成物。
Sauthoff et al. 292. Modification of the p53 Transgene of a Replication-Competent Adenovirus Improves p53 Stability and Cancer Cell Killing
CA3087175A1 (en) An oncolytic virus vector comprising c-terminally truncated herpes simplex virus-thymidine kinase (hsv-tk), compositions and methods of use thereof
Center et al. 581. A Chimeric Fusion of the Human Achaete Scute Homolog 1 (hASH1) and the Enhancer of Zeste Homolog 2 (EZH2) Promoters Is a Promising Regulator of Suicide Gene Therapy in Small Cell Lung Cancer (SCLC)